Next Article in Journal
Differentiation Induction as a Response to Irradiation in Neural Stem Cells In Vitro
Previous Article in Journal
Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation
Review

Whole-blood DNA Methylation Markers for Risk Stratification in Colorectal Cancer Screening: A Systematic Review

1
Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany
2
Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany
3
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
4
German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(7), 912; https://doi.org/10.3390/cancers11070912
Received: 20 May 2019 / Revised: 25 June 2019 / Accepted: 26 June 2019 / Published: 28 June 2019
DNA methylation profiles within whole-blood samples have been reported to be associated with colorectal cancer (CRC) occurrence and might enable risk stratification for CRC. We systematically reviewed and summarized studies addressing the association of whole-blood DNA methylation markers and risk of developing CRC or its precursors. We searched PubMed and ISI Web of Knowledge to identify relevant studies published until 12th November 2018. Two reviewers independently extracted data on study population characteristics, candidate genes, methylation measurement methods, methylation levels of patients in comparison to healthy controls, p-values, and odds ratios of the markers. Overall, 19 studies reporting 102 methylation markers for risk assessment of colorectal neoplasms met our inclusion criteria. The studies mostly used Methylation Specific Polymerase Chain Reaction (MS-PCR) for assessing the methylation status of a defined set of genes. Only two studies applied array-based genome-wide assays to assess the methylation levels. Five studies incorporated panels consisting of 2–10 individual methylation markers to assess their potential for stratifying the risk of developing colorectal neoplasms. However, none of these associations was confirmed in an independent cohort. In conclusion, whole-blood DNA methylation markers may be useful as biomarkers for risk stratification in CRC screening, but reproducible risk prediction algorithms are yet to be established by large scale epigenome-wide studies with thorough validation of results in prospective study cohorts including large screening populations. The possibilities of enhancing predictive power by combining methylation data with polygenetic risk scores and environmental risk factors need to be explored. View Full-Text
Keywords: DNA methylation; whole blood; colorectal neoplasms; odds ratio; risk stratification DNA methylation; whole blood; colorectal neoplasms; odds ratio; risk stratification
Show Figures

Figure 1

MDPI and ACS Style

Raut, J.R.; Guan, Z.; Schrotz-King, P.; Brenner, H. Whole-blood DNA Methylation Markers for Risk Stratification in Colorectal Cancer Screening: A Systematic Review. Cancers 2019, 11, 912. https://doi.org/10.3390/cancers11070912

AMA Style

Raut JR, Guan Z, Schrotz-King P, Brenner H. Whole-blood DNA Methylation Markers for Risk Stratification in Colorectal Cancer Screening: A Systematic Review. Cancers. 2019; 11(7):912. https://doi.org/10.3390/cancers11070912

Chicago/Turabian Style

Raut, Janhavi R., Zhong Guan, Petra Schrotz-King, and Hermann Brenner. 2019. "Whole-blood DNA Methylation Markers for Risk Stratification in Colorectal Cancer Screening: A Systematic Review" Cancers 11, no. 7: 912. https://doi.org/10.3390/cancers11070912

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop